ArticleFrontiers in medicine2021
Will There Ever Be Cure for Chronic, Life-Changing Colistin-Resistant
Article in Frontiers in medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Real-World Effectiveness of Ceftazidime-Avibactam for Multidrug-Resistant Gram-Negative Pneumonia, Time-Stratified Risk Factors for Short- and Long-Term Mortality, and Inpatient Costs: A Multicenter Retrospective Cohort Study.Infectious diseases and therapy · 2026Article
- Rising Prevalence of Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2025Article
- First detection of multidrug-resistant and toxigenic Pasteurella aerogenes in sow vaginal discharge: a novel threat to swine health in Thailand.Scientific reports · 2024Article
- Ceftazidime-Avibactam Combination Therapy versus Monotherapy for the Treatment Carbapenem-Resistant Gram-Negative Bacterial Infections: A Retrospective Observational Study.Infection and drug resistance · 2024Article
- Interactions and Implications ofInfection and drug resistance · 2024Review
- Case Study and Genomic Analysis of a Hypervirulent ST25Infection and drug resistance · 2024Article
- Risk Factors for Multidrug Resistance in Patients Infected with Carbapenem-ResistantInfection and drug resistance · 2024Article
- Ca-EDTA restores the activity of ceftazidime-avibactam or aztreonam against carbapenemase-producingiScience · 2023Article
- Molecular evaluation of aminoglycosides resistance and biofilm formation inHealth science reports · 2023Article
- Clinical Efficacy and Safety Evaluation of Ceftazidime-Avibactam in the Treatment ofInfection and drug resistance · 2023Article
- The Efficacy and Influencing Factors of Polymyxin B in High-Level Carbapenem-ResistantInfection and drug resistance · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.